Compare Apple Inc (AAPL) vs DexCom, Inc. (DXCM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apple Inc vs DexCom, Inc. — how do they compare? Apple Inc trades at $313.29 (market cap $4.56T), while DexCom, Inc. trades at $74.21 (market cap $28.39B). The key difference: Apple Inc is far larger — about 160.6× DexCom, Inc.'s market cap, and Apple Inc pays a 0.35% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| AAPL | DXCM | |
|---|---|---|
Market Cap | $4.56T | $28.39B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $89.53 |
52-Week Low | $202.38 | $54.84 |
Enterprise Value | $4.58T | $27.36B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $313.28, up 0.2% on the day, with a bullish technical signal and strong support at $309. Recent earnings beats and a 26.91% net margin in 2025 highlight robust profitability. Revenue grew to $416.16B in 2025, with further growth projected to $451.4B in 2026. Positive news includes leading smartphone shipments and institutional buying, though union-busting allegations and potential Q2 2026 earnings miss pose concerns.
Outlook remains positive with a consensus price target of $329.62, offering ~5% upside. Strengths include high margins, cash flow generation, and AI opportunities via 2.5B device base. Risks involve competitive pressures, regulatory scrutiny from EU fines, and reliance on iPhone sales. Analyst sentiment is bullish (63% buy ratings), but investors should monitor execution against earnings expectations.
DXCM trades at $73.57, up 3.26% with a bullish technical outlook and strong fundamental performance. Recent earnings beats and FDA clearances for pediatric use of Stelo CGM support growth. Revenue reached $4.66B in 2025 with net income of $836.30M, reflecting a 19.31% margin. Analyst consensus is strongly bullish with an $83.78 price target.
The outlook remains positive driven by CGM market expansion and international growth, though risks include GLP-1 drug competition and execution in non-insulin markets. Valuation at 31.06 P/E is reasonable for its growth profile, with institutional sentiment favoring further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
